NeoGraph Analytics
PharmaceuticalsNorth America2023 – 2032

Drug Discovery Market Size, Share and Trends Analysis

Global Drug Discovery Market valued at $75.6B in 2023 with 7.1% CAGR through 2032. AI-driven platforms, oncology applications, and North America dominance highlighted. Forecast to reach $135.8B by 2032.

Revenue, 2023

$75.6B

Forecast, 2032

$135.8B

CAGR, 2024-2032

7.1%

Report Coverage

North America

Code: drug-discovery-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Market Overview

The global drug discovery market, valued at $75.6 billion in 2023, is experiencing robust growth driven by AI integration and rising R&D investments, with projections indicating a compound annual growth rate of 7.1% through 2032.

Market Stage

High growth

Adoption Level

Growing

Key Trends

AI/ML adoption accelerating target identification and lead optimizationIncreased use of generative AI for novel molecule designRise of cloud-based computational platforms for collaborative researchGrowing focus on rare diseases and personalized medicine
02

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 7.1%

Base Year (2023)

$78.7B

Forecast (2032)

$135.8B

CAGR (2024-2032)

7.1%

Regional Market Analysis
Market share and growth rate by region

North America

#1
Share: 40.2%CAGR: 5.5%

Largest market: United States

Europe

#2
Share: 30.1%CAGR: 6.2%

Largest market: Germany

03

Market Dynamics

  • Rising prevalence of chronic diseases requiring novel therapies
  • Advancements in AI and machine learning technologies
  • Increasing R&D investments by pharmaceutical companies
  • Aging global population driving demand for new treatments
04

Market Segmentation

By Type

  • Small Molecules
  • Biologics
  • Cell and Gene Therapies

By Application

  • Oncology
  • Central Nervous System Disorders
  • Cardiovascular Diseases
  • Infectious Diseases
  • Rare Diseases

By End User

  • Pharmaceutical Companies
  • Biotechnology Firms
  • Academic Research Institutions
  • Contract Research Organizations
05

Regional Analysis

1

North America

Lead: United States
CAGR: 5.5%Share: 40.2%

Leading region with mature infrastructure and significant investments from major pharma companies and tech giants.

2

Europe

Lead: Germany
CAGR: 6.2%Share: 30.1%

Strong presence of academic research institutions and increasing adoption of digital health initiatives.

3

Asia Pacific

Lead: China
CAGR: 8.5%Share: 25.8%

Rapidly expanding market driven by government initiatives and cost-effective R&D capabilities.

Country-Level Analysis

CountryShareGrowth
United States
28.5%
+5.3%
Germany
12.7%
+6.0%
China
10.3%
+9.1%
06

Competitive Landscape

P

Pfizer

United States

Leader60.2B

Major investments in AI-driven discovery platforms like AI-based target identification and predictive toxicology

AI-driven target identification platformPredictive toxicology models
R

Roche

Switzerland

Leader68.7B

Focus on AI integration in oncology drug discovery and digital pathology solutions

AI-based digital pathology solutionsOncology drug discovery platform
G

GSK

United Kingdom

Challenger

Developing AI platforms for target validation and compound optimization in respiratory and infectious diseases

I

Insilico Medicine

Hong Kong

Challenger0.35B

Pioneering generative AI for de novo molecular design and aging research applications

Pharma.AI platformGenerative AI for molecular design
R

Recursion Pharmaceuticals

United States

Follower

Utilizing AI-powered phenotypic screening platforms for target discovery

07

Recent Developments

25
2025Eli Lilly

Launch of AI-powered small molecule discovery platform for oncology targets

24
2024DeepMind

Release of AlphaFold 3 with enhanced capabilities for protein-ligand interactions and drug design

24
2024NVIDIA

Partnership with multiple pharma companies to deploy AI-driven drug discovery platforms on its Grace Hopper supercomputers

24
2024BMS

Acquisition of AI startup for target identification in immuno-oncology

23
2023AstraZeneca

Collaboration with Google DeepMind on AI-based drug discovery projects

08

Regulatory Landscape

FDA's 2023 guidance on AI/ML-based software as a medical device in drug discoveryEU's AI Act with specific provisions for high-risk health applicationsEMA's evolving framework for evaluating AI-assisted clinical trials
09

Frequently Asked Questions

The global drug discovery market was valued at $75.6 billion in 2023 and is projected to reach $135.8 billion by 2032.
The market is expected to grow at a compound annual growth rate (CAGR) of 7.1% from 2024 to 2032.
AI/ML Platforms represent the largest segment, capturing approximately 35.2% of the market share as of 2023.
North America currently holds the largest market share at 40.2%, driven primarily by the United States.